Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact Sciences

ISIN: US30063P1057, WKN: 590273

Market price date: 04.06.2021
Market price: 106,83 USD

Exact Sciences Fundamental data and company key figures of the share

Annual reports in USD
Key figures 25-02-2021
Cash flow
Net operating cash flow 136.482.000
Capital Expenditures -64.352.000
Free cash flow 72.130.000
Balance sheet
Total Equity 2.823.490.000
Liabilities & Shareholders equity 4.925.090.000
Income statement
Net income -848.533.000
Eps (diluted) -5,610
Diluted shares outstanding 159.423.000
Net sales/revenue 1.491.390.000

Fundamental ratios calculated on: 04-06-2021

Key figures 04-06-2021
Cash flow
P/C 124,79
P/FC 236,12
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization17.031.158.784,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company´s Cologuard test is a non-invasive, stool-based DNA (sDNA) screening test designed to detect deoxyribonucleic acid (DNA) markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company´s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85% at a specificity of 90%.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,